DaVita HealthCare Partners Now Covered by Analysts at Susquehanna (DVA)
Analysts at Susquehanna initiated coverage on shares of DaVita HealthCare Partners (NYSE:DVA) in a research report issued to clients and investors on Monday. The firm set a “neutral” rating on the stock.
In other DaVita HealthCare Partners news, Insider Kim M. Rivera sold 5,929 shares of DaVita HealthCare Partners stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $71.05, for a total value of $421,255.45. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
DaVita HealthCare Partners (NYSE:DVA) traded down 0.03% on Monday, hitting $70.77. The stock had a trading volume of 1,063,857 shares. DaVita HealthCare Partners has a 52 week low of $52.75 and a 52 week high of $72.37. The stock has a 50-day moving average of $69.29 and a 200-day moving average of $66.4. The company has a market cap of $15.159 billion and a price-to-earnings ratio of 19.36.
DaVita HealthCare Partners (NYSE:DVA) last released its earnings data on Thursday, May 1st. The company reported $0.85 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.86 by $0.01. The company had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $3.02 billion. During the same quarter last year, the company posted $1.84 earnings per share. DaVita HealthCare Partners’s revenue was up 7.5% compared to the same quarter last year. Analysts expect that DaVita HealthCare Partners will post $3.69 EPS for the current fiscal year.
A number of other analysts have also recently weighed in on DVA. Analysts at Deutsche Bank reiterated a “buy” rating on shares of DaVita HealthCare Partners in a research note on Friday, May 2nd. They now have a $77.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of DaVita HealthCare Partners in a research note on Friday, May 2nd. They now have a $73.00 price target on the stock. Finally, analysts at Piper Jaffray raised their price target on shares of DaVita HealthCare Partners from $73.00 to $76.00 in a research note on Friday, May 2nd. They now have an “overweight” rating on the stock. One analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $83.25.
DaVita HealthCare Partners Inc, formerly DaVita Inc, is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease (NYSE:DVA).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.